Lobbying

Blue Cross and Blue Shield of Florida's latest lobbying report covers Q2 2026, at $80K. The four quarters Q4 2025–Q3 2026 total $300K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.

Blue Cross and Blue Shield of Florida

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$300K
Last 4 quarters
vs last quarter
−100.0%
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Blue Cross and Blue Shield of Florida lobbying by quarter
Blue Cross and Blue Shield of Florida lobbying by quarter
QuarterAmountReports
Q4 2022$160K1
Q1 2023$180K1
Q2 2023$240K1
Q3 2023$120K1
Q4 2023$150K1
Q1 2024$210K1
Q2 2024$240K1
Q3 2024$220K1
Q4 2024$140K1
Q1 2025$210K1
Q2 2025$120K1
Q3 2025$80K1
Q4 2025$90K1
Q1 2026$130K1
Q2 2026$80K1
Q3 2026$00

By issue

  • Health issues$776.7K · 15 reports
  • Medicare and Medicaid$776.7K · 15 reports
  • Pharmacy$776.7K · 15 reports
  • Taxation$40K · 1 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • Centers For Medicare and Medicaid Services (CMS)15 reports
  • Executive Office of the President (EOP)15 reports
  • Health & Human Services, Dept of (HHS)15 reports
  • HOUSE OF REPRESENTATIVES15 reports
  • Labor, Dept of (DOL)15 reports
  • Office of Management & Budget (OMB)15 reports
  • SENATE15 reports
  • White House Office15 reports

Firms it paid

Firm
In-houseBlue Cross and Blue Shield of Florida$2.4M15 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

Filed by
07/20for Q2In-house$80K
04/20for Q1In-house$130K
01/20for Q4 2025In-house$90K
25/10/20for Q3 2025In-house$80K
25/07/21for Q2 2025In-house$120K
25/04/21for Q1 2025In-house$210K
25/01/17for Q4 2024In-house$140K
24/10/17for Q3 2024In-house$220K
24/07/19for Q2 2024In-house$240K
24/04/18for Q1 2024In-house$210K
24/01/19for Q4 2023In-house$150K
23/10/19for Q3 2023In-house$120K
23/07/19for Q2 2023In-house$240K
23/04/20for Q1 2023In-house$180K
23/01/18for Q4 2022In-house$160K